Your browser is old and is not supported. Upgrade for better security.

Invest in Aphios Pharma LLC

Aphios® Pharma is developing cannabis-based therapeutics for anxiety, pain, opioid use disorder & MS

Pitch Video
Investor Panel

Highlights

1
Green biotech developing sustained release nanoencapsulated cannabinoids for highly unmet chronic medical needs
2
ESG opportunity addressing a $4B market for cancer pain, $5B for opioid use disorder and $40B for Multiple Sclerosis
3
Aphios has spent $44 million to date on developing enabling drug manufacturing and drug delivery technologies
4
Including $7.9M in peer-reviewed grants from National Cancer Institute, National Institute on Drug Abuse and NCCIH, NIH
5
Established supercritical fluid manufacturing facility for 1,000 kg pharma-grade cannabinoids per yr under cGMP
6
Fully-equipped Schedule I BSL-2 labs and cGMP suites for formulation and nanoencapsulation of cannabinoids
7
Our proprietary manufacturing and nanoencapsulation technologies are protected by 16 issued patents and 4 provisionals
8
We are dedicated to sustainability, environmental responsibility and communal curtailment of climate change

Our Team

Medical marijuana has proven to be partially effective for cancer pain, opioid addiction and Multiple Sclerosis. These effects are acute and not effective for the treatment for chronic diseases such as pain and opioid addiction. With nanoencapsulation, we can improve the delivery and efficacy of cannabinoids.

Pitch

Overview